Evidence map›Paper›PMID 8558551›Full record

ArticleJournal of medical genetics1995

General overgrowth in the fragile X syndrome: variability in the phenotypic expression of the FMR1 gene mutation.

B B de Vries, H Robinson, I Stolte-Dijkstra, C V Tjon Pian Gi, P F Dijkstra, J van Doorn, D J Halley, B A Oostra, G Turner, M F Niermeijer

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical genetics, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 40 citations in OpenAlex.

  1. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives.The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2015
    Trial
  2. Article
  3. Article
  4. Article
  5. Frontiers in endocrinology · 2019
    Article
  6. Fragile X syndrome: A review of clinical management.Intractable & rare diseases research · 2016
    Review
  7. Review
  8. The fragile X syndrome.Journal of medical genetics · 1998
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

B B de VriesDepartment of Clinical Genetics, University Hospital Dijkzigt, Rotterdam, The Netherlands.
H Robinson
I Stolte-Dijkstra
C V Tjon Pian Gi
P F Dijkstra
J van Doorn
D J Halley
B A Oostra
G Turner
M F Niermeijer
Erasmus University Rotterdam · NLErasmus MC · NLPrince of Wales Hospital · AUAcademic Medical Center · NLRotterdam University of Applied Sciences · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

RNA-Binding ProteinsAdultChild, PreschoolFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeGrowth DisordersHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMaleMutationNerve Tissue ProteinsPedigreePhenotypeFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor INerve Tissue ProteinsRNA-Binding Proteins

Identifiers

PMID8558551
PMCPMC1051696
OpenAlexW2034136228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.